What is rPFS in prostate cancer?
Radiographic progression-free survival (rPFS) as defined by the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) is a candidate end point that represents a clinically meaningful benefit to patients.
What is radiographic progression in cancer?
Radiographic progression was defined as either Response Evaluation Criteria In Solid Tumors (RECIST) or bone scan progression defined as two or more new lesions at the initial after treatment assessment confirmed by additional lesions ≥6 weeks later, or two or more new lesions at any time beyond the initial post- …
What is a PFS event?
Progression-free survival (PFS) is defined as the time from random assignment in a clinical trial to disease progression or death from any cause.
What is clinical progression?
Advance of disease that can be measured by observable and diagnosable signs or symptoms.
How is overall survival calculated?
The overall survival rate is often stated as a five-year survival rate, which is the percentage of people in a study or treatment group who are alive five years after their diagnosis or the start of treatment.
What company makes xtandi?
XTANDI® (enzalutamide) Approved by U.S. FDA for the Treatment of Metastatic Castration-Sensitive Prostate Cancer | Pfizer.
What is treatment free survival?
Treatment-free survival (TFS) was defined as the area between Kaplan-Meier curves for two conventional time-to-event end points, each defined from random assignment: time to immune checkpoint inhibitor (ICI) protocol therapy cessation and time to subsequent systemic therapy initiation or death.
What is overall survival in cancer?
Listen to pronunciation. (oh-ver-AWL ser-VY-vul) The length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.
What is the difference between OS and PFS?
Progression-free survival (PFS), the time from treatment initiation until disease progression or worsening, may be used as a direct or surrogate measure of clinical benefit for drug approvals, depending on the disease and response observed, while overall survival (OS), the duration of patient survival from the time of …
What is the difference between PFS and DFS?
Disease-Free Survival (DFS), also known as Relapse-Free Survival (RFS), is often used as a primary endpoint in phase III trials of adjuvant therapy. Progression-Free Survival (PFS) is used commonly as a primary endpoint in phase III trials evaluating treatment of metastatic cancer.
What is progression of a disease?
Disease progression describes the natural history of disease, such as pain, or biomarker of drug response, such as blood pressure. The action of a drug, such as inhibiting an enzyme or activating a receptor, leads to a change in disease status over time.
What is a prognosis of a disease?
Listen to pronunciation. (prog-NO-sis) The likely outcome or course of a disease; the chance of recovery or recurrence.
How is radiographic progression free survival ( RPFS ) defined?
Radiographic progression-free survival (rPFS) as defined by the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) is a candidate end point that represents a clinically meaningful benefit to patients. Objective: To demonstrate the robustness of the PCWG2 definition and to examine the relationship between rPFS and OS.
What is radiographic progression free survival in prostate cancer?
Radiographic progression-free survival (rPFS) as defined by the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) is a candidate end point that represents a clinically meaningful benefit to patients.
Is there a correlation between RPFS and OS?
Conclusions and relevance: Sensitivity analyses in PREVAIL demonstrated the robustness of the PCWG2 rPFS definition using additional measures of progression. There was concordance between central and investigator review and a positive correlation between rPFS and OS among enzalutamide-treated patients.
Why is OS important for metastatic prostate cancer?
Importance: Drug development for metastatic castration-resistant prostate cancer has been limited by a lack of clinically relevant trial end points short of overall survival (OS).